> > 臨床腫瘍グループ

臨床腫瘍グループ

 基礎研究                            

基礎研究1

1)肺癌細胞株とマウスモデル(A/Jマウス,EGFR遺伝子改変マウス,ヌードマウス)を使用した上皮成長因子受容体(Epidermal growth factor receptor: EGFR)シグナルの解析

  • EGFRと血管新生を阻害する新規分子標的薬剤であるvandetanib耐性肺腺癌株の樹立と耐性機序の解析
  • EGFR耐性肺腺癌株におけるmicroRNAの役割と耐性解除
  • NNK発癌およびcisplatin発癌A/Jマウスにおけるvandetanibによる発癌抑制
  • EGFR mouse 15 deletion変異マウスの作製
  • EGFR mouse 15 deletion変異発癌マウスに対するvandetanibの効果と耐性機序の解明
  • EGFR human L858R変異発癌マウスにおけるgefitinibおよびvandetanibの効果
  • EGFR human L858R変異マウスにおけるgefitinibおよびvandetanibによる発癌抑制
  • EGFR human L858R変異マウスに対するHDAC阻害剤の効果と耐性機序の解明
  • 早期gefitinib耐性マウスモデルの作製と解析
  • EGFR遺伝子変異陽性肺癌細胞株のマウスモデルに対する殺細胞性抗癌剤の有用性
  • すりガラス陰影を伴う肺腺癌の進展におけるEGFRシグナルの関与
  • マウスモデルにおけるEGFR遺伝子変異を生じる機序の解明
  • 肺癌患者の呼気凝集液を用いたEGFR遺伝子変異解析
  • PTEN欠損gefitinib耐性肺腺癌株の耐性解除

基礎研究 2

    • 2)癌幹細胞

    • EGFR遺伝子改変マウスより細気管支肺胞幹細胞の分離と解析
    • 肺小細胞癌における癌幹細胞の役割

3)癌精巣抗原

    • 肺腺癌細胞株における癌精巣抗原の発現とその機能解析

4)メチル化

    • 胸水DNAのメチル化診断による胸膜中皮腫の早期発見

5)一塩基遺伝子多型性(Single Nucleotide Polymorphism: SNP)

    • 肺癌患者の血球を用いたSNP解析

6) COPD肺癌モデル

  • COPDより肺発癌マウスモデルの作製
  • これらの基礎研究に対する2009年度の文部科学省科学研究費(挑戦的萌芽研究,基盤研究)として,「上皮成長因子受容体遺伝子 変異陽性肺癌の根治治療開発を目指した動物実験モデルの樹立(木浦)」,「非喫煙者肺癌モデルを用いた細気管支肺胞上皮癌より浸潤癌への進展機構の解明 (瀧川)」を獲得しています。

 臨床研究                          

臨床研究

  • 大学院生臨床研究(がんプロ)

  • 進展型小細胞癌に対する化学療法1コース目の腫瘍縮小と予後の関連
  • Erlotinibの臨床成績
  • COPD合併進行肺非小細胞癌の予後
  • 肺癌の化学療法の進歩 ー第III相試験の経年的変化ー
  • 肺癌副腎転移に対する集学的治療
  • 5年以上生存した手術不能,根治的放射線療法不能の肺癌患者の解析
  • 胚細胞性腫瘍に対する自家末梢血幹細胞移植を組み込んだ集学的治療
  • 肉腫に対するイホスファミドとエピルビシン併用化学療法の成績
  • OLCG/JCOGS

  • 岡山肺癌治療研究会(OLCSG)の事務局として,多くの臨床試験を施行してします。 また,日本臨床腫瘍グループ(JCOG)の一員として臨床試験に協力しています。

 論文・業績                      

Publication from OLCSG

Small Cell Lung Cancer (clinical trial)

  • Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer. Cancer 1993
  • Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. Lung Cancer 1993
  • Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer: a 5- to 11-year follow-up. Intern Med 1993
  • Mortality and morbidity in two-year disease-free survivors of small cell lung cancer after treatment with combination chemotherapy with or without irradiation. Acta Medica Okayama 1993
  • A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up. Cancer 1998
  • Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. Jpn J Cancer Chemother 2002
  • Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer 2003
  • Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study. Anticancer Res 2003
  • A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Cancer Chemother Parmacol 2007

Non-Small Cell Lung Cancer (clinical trial)

  • Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. Acta Med Okayama 1991
  • A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Br J Cancer 2000
  • Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group Br J Cancer 2001
  • A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 2002
  • Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003
  • Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol 2004
  • A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol 2007
  • Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer.Anticancer Res 2006
  • Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial. J Thoracic Oncol 2007

Combination phase I trial

  • Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br J Cancer 1999
  • Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer. Lung Cancer 2004
  • A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2004
  • Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Anticancer Res 2005
  • A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. Cancer Chemother Pharmacol 2006
  • A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.. Lung Cancer 2006
  • A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer. Lung Cancer 2009

Meta-analysis

  • A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992
  • Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999

Others

  • Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group Trials. Acta Med Okayama 1998
  • Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol 2005
  • Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005
  • Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005
  • Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study. Lung Cancer 2005
  • Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer 2006
  • Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 2008
  • Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol 2009

現在進行中の主な臨床試験

  • OLCSG 0102: Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
  • OLCSG 0401: Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancer
  • OLCSG 0403: Randomized comparative study of cisplatin, docetaxel, and irinotecan versus cisplatin and docetaxel in patients with stage IIIB or stage IV non-small cell lung cancer
  • OLCSG 0501:Phase I/II study of cisplatin and S-1 with concurrent thoracic radiation therapy for inoperable locally advanced non-small-cell lung cancer
  • OLCSG 0502: Phase I/II study of S-1 with concurrent thoracic radiation therapy for elderly inoperable locally advanced non-small-cell lung cancer
  • OLCSG 0503: Randomized phase II trial of S-1 plus docetaxel combination versus single-agent docetaxel in platinum-pretreated patients with non-small-cell lung cancer
  • OLCSG 0704: Phase II study of cisplatin, docetaxel, and irinotecan, followed by gefitinib, gemcitabine and vinorelbine for patients with non-small-cell lung cancer harboring active EGFR gene mutations
  • OLCSG 0705: Phase II study of erlotinib monotherapy for relapsed patients with non-small-cell lung cancer who do not possess any active EGFR gene mutations

OLCSG参加施設

Participating institutions to OLCSG

  • Okayama University Hospital, Okayama
  • Shikoku Cancer Center Hospital, Matsuyama
  • Sumitomo Besshi Hospital, Niihama
  • Chugoku Central Hospital, Fukuyama
  • Yamaguchi Ube Medical Center, Ube
  • Okayama Red Cross General Hospital, Okayama
  • Ehime Prefectural Central Hospital, Matsuyama
  • Okayama Rosai Hospital, Okayama
  • Kure Kyosai Hospital, Kure
  • Okayama Medical Center, Okayama
  • Minami-Okayama Medical Center, Hayashima
  • Fukuyama Medical Center, Fukuyama
  • Tsuyama Central Hospital, Tsuyama
  • Kawasaki Hospital, Okayama
  • Kagawa Rosai Hospital, Marugame
  • Yashima General Hospital, Takamatsu
  • Okayama Saiseikai General Hospital, Okayama
  • Kurashiki Central Hospital, Kurashiki

学会活動

国内学会

  •  国内学会では,内科学会,日本臨床腫瘍学会,呼吸器学会,呼吸器内視鏡学会,癌学会,癌治療学会,肺癌学会をはじめ,シンポジウム, ワークショップを含め数多くの発表をしています。海外では,大学院生の研究成果の発表の場である米国癌学会(AACR)(若手奨励賞過去4度受賞,ミニシ ンポジウム5名)に毎年4-5演題,また米国臨床腫瘍学会(ASCO)でも毎年2-3演題が発表を受理されています。
gakkaiphoto1
gakkaiphoto2
otherwindow 画像をクリックすると拡大します。

国際学会

国際学会中の休憩時間

kokusaiphoto

課外活動

    •  当グループの大学院生の課外活動には目を見張るものがあります。富士登山,大山登山,屋久島周遊,マラソン大会,水泳大会,レガッ タ大会,ボーリング,野球,サックス演奏,お誕生日会など,大学生(家族ぐるみ)のサークル活動にも勝るとも劣らない勢いです。「よく学び,よく遊び」の 精神で楽しんでいます。
kagaikatsudo